Sakar Healthcare

Quick check

The five things to look at first. Open one for more.

• DebtLow debtIt owes ₹46 Cr against ₹346 Cr of shareholders' money (Sep 2026), 0.13 times.
• ResultsGrowingIn the Sep 2026 quarter, sales rose 50% and profit rose 120% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 52%, down from 53% in Sep 2025.
• ValuationNormal for this stockThe share trades at 51.3 times its yearly earnings (P/E), pricier than 62% of the time in the last 5 years. Its usual P/E is about 41.

Sakar Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)51.3 against a typical 34.3: pricier than most peers (1st = cheapest).159th of 220
• Sales growth+50% against a typical +15.6% from a year earlier.31st of 197
• Profit growth+120% against a typical +18.9% from a year earlier.26th of 160
• Share price, 3 months+17.2% against a typical −0.5%.43rd of 200
• Size₹ 1,953.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).72nd of 199

Exchange filings and their impact on the company.

• 23 Oct 2026Outcome of Board MeetingHigh impactVery positivePrice −6.5% that day
  Strong Q2 with revenue up 52% and profit up 149% YoY points to 30%+ full-year growth.

  Sakar Healthcare reported strong Q2 FY27 results with revenue from operations of Rs 87.4 crore, up 52% from Rs 57.6 crore a year ago, and net profit of Rs 11.3 crore, up 149% from Rs 4.5 crore. For the first half, revenue was Rs 160.4 crore and profit was Rs 21.6 crore, already 71% of last full year's profit. The growth with improved operating margins and lower borrowings points to materially higher earnings over the next 12 months.

  Full analysisFiling
• 14 Oct 2026General UpdatesMedium impactPositivePrice +7.3% that day
  Sakar started commercial oncology exports on 22 global approvals, lifting near-term growth outlook.

  Sakar Healthcare said its oncology export push is underway, with 22 marketing authorisations granted out of 190 filed across EU, UK, APAC, Canada and LatAm, plus 11 site-variation approvals involving MNCs and 2 CEP approvals. Commercial supplies have started from its EU-GMP approved, API-integrated oncology formulation site. The company added its business is mainly oncology exports, so the proposed domestic MRP cap on oncology products does not affect it.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Sanjay Surendra Shah

Chairman of the Board, Managing Director

Dharmesh R. Thaker

Chief Financial Officer

Sudhir Ghule

Chief Operating Officer

Bharat S. Soni

Compliance Officer, Company Secretary

Aarsh Sanjay Shah

Joint Managing Director, Director

Sunil Marathe

Whole Time Director - Technical